Caredx, INC 10-K annual reports

CareDx, a precision medicine company, reported a 14% increase in total revenue to $379.8 million for fiscal year 2025, alongside a net loss of $21.4 million, while successfully remediating a material weakness in internal controls and settling a securities class action.

CareDx achieved profitability in 2024, driven by revenue growth and strategic initiatives, while addressing regulatory challenges and focusing on operational excellence.

CareDx, Inc.'s recent SEC filing details its capital stock structure, voting rights, and measures designed to deter hostile takeovers.